
"I am glad that taking part in a trial might help others on their own cancer journey.”
This trial looked at the timing of chemotherapy after surgery for bladder cancer. The trial was for people with bladder cancer that had grown through the muscle wall or had spread to nearby . This trial was supported by Cancer Research UK.
If bladder cancer has grown through the muscle layer of the bladder, it is called invasive bladder cancer. Doctors usually treat invasive bladder cancer with surgery or radiotherapy. But sometimes the cancer can come back after treatment.
In this trial, researchers tried to find out if having chemotherapy after surgery could help to treat invasive bladder cancer. But because chemotherapy has , it is important that people don't have treatments they don't need.
The aims of the trial were to find out if it is better
The trial team found that having chemotherapy straight after surgery didn’t increase the average time people lived after treatment.
284 people with muscle invasive bladder cancer or bladder cancer that had spread to the lymph nodes took part in this trial. Everyone had already had their bladder removed (radical cystectomy). They were put into 1 of 2 groups at random
The researchers looked at the number of people whose cancer hadn’t got worse 5 years after the trial started. Doctors call this progression free survival. They found this was
The researchers also looked at the number of people living 7 years after the trial started. Doctors call this overall survival. They found no significant difference between the 2 different groups. So having chemotherapy straight after surgery is no better than having it if the cancer comes back.
The trial team hoped that about 660 people could join this trial but it was difficult to find enough people with this type of cancer to take part. The researchers think it is possible that that some sub groups could benefit from immediate chemotherapy, but as they didn’t recruit enough people they can’t say for sure. They suggest that future trials could possibly look at chemotherapy after surgery for these sub groups. For example, if future research identifies patients who are at very high risk of the cancer coming back or if they have cancer which future research shows is particularly sensitive to chemotherapy.
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists () and published in a medical journal. The figures we quote above were provided by the trial team who did the research. We have not analysed the data ourselves.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Michael Leahy
Cancer Research UK
European Organisation for Research and Treatment of Cancer (EORTC)
NIHR Clinical Research Network: Cancer
University of Leeds
This is Cancer Research UK trial number CRUK/02/009.
Freephone 0808 800 4040
"I am glad that taking part in a trial might help others on their own cancer journey.”